YOLFTbeta
IQVIA Holdings Inc

IQVIA Holdings Inc

IQV · NYSE · Healthcare / Diagnostics & Research

265.12USD-5.99 (-2.21%)

Price History

Full chart

Market Stats

Previous Close271.11
Open271.72
Day Range263.50 – 272.12
52-Week Range154.50 – 284.50
Volume1.98M
Market Cap45.35B
P/E (TTM)33.48
Forward P/E18.59
EPS8.22
Dividend Yield0.00%
Beta1.17
50-Day Avg265.35
200-Day Avg209.22

About

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Ari Bousbib
  • Employees93.00K
  • Headquarters2400 Ellis Road, Durham, NC, United States, 27703, USA
  • Websitehttps://www.iqvia.com

Leadership

  • Mr. Ari BousbibCEO & Chairman · b. 1961
  • Mr. Eric M. Sherbet J.D.Executive VP, General Counsel & Secretary · b. 1964
  • Mr. W. Richard Staub IIIPresident of Research & Development Solutions · b. 1963
  • Mr. Alistair GrenfellPresident of Commercial Solutions · b. 1974
  • Mr. Michael J. Fedock MBAExecutive VP & Chief Financial Officer · b. 1976
  • Mr. James G. BerkshireExecutive Vice President of Global Infrastructure & Operations · b. 1974
  • Ms. Keriann CherofskySenior VP, Corporate Controller & Chief Accounting Officer · b. 1985
  • Dr. Jeffrey A. Spaeder M.D.Chief Medical & Scientific Officer
  • Mr. Duane SachsSenior Vice President of Corporate Development
  • Ms. Trudy SteinChief Human Resources Officer & Executive VP

Financials

Income Statement

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.92B4.33B4.87B5.10B5.46B5.74B6.82B9.70B10.41B11.09B11.36B13.87B14.41B14.98B15.40B16.31B
Growth (%)-+10.29%+12.43%+4.81%+7.07%+5.07%+18.79%+42.36%+7.32%+6.49%+2.44%+22.14%+3.86%+3.98%+2.81%+5.87%
Cost of Revenue2.80B3.19B3.63B3.76B3.96B4.12B4.75B6.30B6.75B7.30B7.50B9.23B9.38B9.74B10.03B10.88B
Gross Profit1.12B1.14B1.23B1.34B1.50B1.62B2.07B3.40B3.67B3.79B3.86B4.64B5.03B5.24B5.38B5.43B
Gross Margin28.52%26.39%25.34%26.22%27.49%28.26%30.33%35.05%35.21%34.16%33.97%33.45%34.89%34.96%34.89%33.29%
Operating Expense724.18M796.71M836.50M874.58M910.61M974.39M1.43B2.68B2.92B3.01B3.13B3.25B3.23B3.26B3.17B3.25B
Operating Income395.00M345.25M396.44M462.33M590.39M646.61M642.00M719.00M741.00M777.00M731.00M1.39B1.80B1.98B2.20B2.18B
Operating Margin10.07%7.98%8.15%9.07%10.81%11.27%9.42%7.41%7.12%7.01%6.44%10.04%12.48%13.19%14.29%13.38%
EBITDA467.37M385.74M500.09M554.13M723.00M768.00M849.00M1.65B1.88B2.00B2.08B2.77B2.91B3.26B3.45B2.94B
EBITDA Margin11.91%8.91%10.28%10.87%13.24%13.39%12.46%17.02%18.08%18.05%18.28%19.94%20.19%21.73%22.41%18.01%
Net Income160.60M241.77M177.55M226.59M356.38M387.20M115.00M1.31B259.00M191.00M279.00M966.00M1.09B1.36B1.37B1.36B
Net Income Margin4.09%5.59%3.65%4.44%6.53%6.75%1.69%13.49%2.49%1.72%2.46%6.96%7.57%9.06%8.91%8.34%
R&D-9.45M10.43M4.96M4.98M3.34M000-------
R&D as % of Total Revenue-0.22%0.21%0.10%0.09%0.06%0.00%0.00%0.00%-------
Interest Expense141.43M109.06M134.37M123.51M100.59M101.79M144.00M346.00M414.00M447.00M416.00M375.00M416.00M672.00M670.00M729.00M
Interest Expense % of Total Revenue3.60%2.52%2.76%2.42%1.84%1.77%2.11%3.57%3.98%4.03%3.66%2.70%2.89%4.48%4.35%4.47%

Balance Sheet

Currency: USD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--2.32B2.50B3.07B3.31B3.93B21.21B22.74B22.55B23.25B24.56B24.69B25.34B26.68B26.90B29.94B
Total Liabilities--3.29B3.86B3.73B4.01B4.26B12.35B14.38B15.60B16.99B18.28B18.65B19.57B20.57B20.83B23.31B
Total Equity---970.38M-1.36B-667.41M-704.01M-335.68M8.63B8.11B6.71B6.00B6.00B6.04B5.76B6.11B6.07B6.50B
Cash--516.30M567.73M778.14M867.36M977.15M1.20B959.00M891.00M837.00M1.81B1.37B1.22B1.38B1.70B1.98B
Total Debt--1.97B2.42B2.05B2.29B2.47B7.20B10.22B11.01B12.04B12.90B12.44B13.01B13.90B14.16B16.17B
Net Debt--1.46B1.85B1.27B1.43B1.49B6.00B9.27B10.12B11.20B11.09B11.07B11.79B12.52B12.45B14.19B

Cash Flow

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow378.16M160.95M335.70M397.37M431.75M475.69M860.00M970.00M1.25B1.42B1.96B2.94B2.26B2.15B2.72B2.65B
Investing Cash Flow-141.43M-224.84M-132.23M-240.18M-173.11M-66.95M1.73B-1.19B-810.00M-1.19B-796.00M-2.10B-2.01B-1.60B-1.44B-2.31B
Financing Cash Flow-153.08M-59.31M-146.87M70.96M-130.34M-249.25M-2.28B-72.00M-452.00M-276.00M-217.00M-1.24B-329.00M-382.00M-878.00M-150.00M
Capital Expenditure80.24M75.68M71.34M92.35M82.65M78.39M164.00M369.00M459.00M582.00M616.00M640.00M674.00M649.00M602.00M603.00M
Free Cash Flow297.92M85.27M264.37M305.02M349.10M397.30M696.00M601.00M795.00M835.00M1.34B2.30B1.59B1.50B2.11B2.05B
Dividends Paid67.49M288.32M567.85M2.07B425.00M2.25B638.00M7.16B4.08B11.00M44.00M59.00M----
FCF to OCF78.78%52.98%78.75%76.76%80.86%83.52%80.93%61.96%63.40%58.93%68.56%78.25%70.18%69.80%77.84%77.28%
Dividend Paid to FCF22.65%338.11%214.80%679.72%121.74%565.95%91.67%1191.85%512.70%1.32%3.28%2.56%----

Earnings

Report DateMay 10, 2013Aug 1, 2013Oct 31, 2013Feb 13, 2014May 1, 2014Jul 31, 2014Oct 30, 2014Feb 12, 2015Apr 29, 2015Jul 29, 2015Oct 28, 2015Feb 11, 2016May 3, 2016Jul 27, 2016Nov 2, 2016Feb 14, 2017May 3, 2017Aug 3, 2017Oct 26, 2017Feb 14, 2018May 2, 2018Jul 24, 2018Oct 22, 2018Feb 14, 2019May 1, 2019Jul 24, 2019Oct 30, 2019Feb 12, 2020Apr 28, 2020Jul 22, 2020Oct 20, 2020Feb 10, 2021Apr 22, 2021Jul 27, 2021Oct 21, 2021Feb 15, 2022Apr 27, 2022Jul 21, 2022Oct 26, 2022Feb 10, 2023Apr 27, 2023Aug 1, 2023Nov 1, 2023Feb 14, 2024May 2, 2024Jul 22, 2024Oct 31, 2024Feb 6, 2025May 6, 2025Jul 22, 2025Oct 28, 2025Feb 5, 2026May 5, 2026Jul 28, 2026Oct 27, 2026
EPS Estimate-0.460.510.550.550.610.640.670.710.700.810.870.860.900.981.050.961.051.141.341.271.231.391.471.511.491.571.721.481.061.542.001.862.082.122.432.422.382.382.762.412.372.452.822.482.562.813.112.632.772.983.402.822.722.94
EPS Actual0.360.500.540.580.680.650.650.710.720.780.940.900.890.931.000.461.011.091.191.401.341.291.421.501.531.531.601.741.501.181.632.112.182.132.172.552.472.442.482.782.452.432.492.842.542.642.843.122.702.813.003.422.902.752.95
Surprise-8.70%5.88%5.45%23.64%6.56%1.56%5.97%1.41%11.43%16.05%3.45%3.49%3.33%2.04%-56.19%5.21%3.81%4.39%4.48%5.51%4.88%2.16%2.04%1.32%2.68%1.91%1.16%1.35%11.32%5.84%5.50%17.20%2.40%2.36%4.94%2.07%2.52%4.20%0.72%1.66%2.53%1.63%0.71%2.42%3.13%1.07%0.32%2.66%1.44%0.67%0.59%2.84%1.10%0.34%
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap45.35B
Enterprise Value59.88B
Trailing P/E33.48
Forward P/E18.59
PEG Ratio0.98
Price / Sales2.62
Price / Book6.72
EPS8.22
Book Value40.41
Revenue (TTM)17.31B
Gross Profit (TTM)5.72B
EBITDA3.12B
Profit Margin8.05%
Operating Margin13.73%
Return on Equity21.39%
Return on Assets5.08%
Shares Outstanding164.80M
Shares Float156.44M
Beta1.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 21 analystsTarget 308.65
  • Strong Buy
    16
  • Buy
    3
  • Hold
    2

Ownership Breakdown

Institutions
103.15%
Insiders
1.08%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    14.55M8.84%
  • Harris Associates L.P.
    12.18M7.40%
  • Vanguard Capital Management, LLC
    10.91M6.63%
  • State Street Corp
    7.51M4.56%
  • Vanguard Portfolio Management, LLC
    7.50M4.56%
  • JPMorgan Chase & Co
    6.14M3.73%
  • Artisan Partners Limited Partnership
    4.74M2.88%
  • Boston Partners Global Investors, Inc
    4.47M2.71%
  • Geode Capital Management, LLC
    4.45M2.71%
  • Amvescap Plc.
    3.28M1.99%
  • Morgan Stanley - Brokerage Accounts
    2.71M1.64%
  • NORGES BANK
    2.26M1.38%
  • Franklin Templeton Inc
    2.11M1.28%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    5.23M3.17%
  • Vanguard 500 Index Investor
    4.32M2.63%
  • Vanguard MStar Mid Cap Index Instl
    3.52M2.14%
  • Oakmark Investor
    2.33M1.42%
  • iShares Core S&P 500 ETF
    2.19M1.33%
  • Fidelity 500 Index
    2.17M1.32%
  • Oakmark Select Investor
    2.14M1.30%